Other groups achieved similar results with other TLR agonists (mainly R848 or CpG, agonist of TLR9) or STING agonists (mainly cGAMP),5 6 often testing the combination of these drugs with ICIs to enhance T cell response; with radiotherapy or immunogenic cell death inducers to kill cancer cells and enhance antitumor immunity (ie, releasing damage-associated molecular patterns and tumor antigens). Here, STING1 is linked to cancer.